Investors and analysts scrambled Thursday to divine portent from a heap of newly released abstracts previewing December's American Society of Hematology (ASH) annual meeting. Karyopharm Therapeutics Inc. led the pack of abstract news gainers, with shares (NASDAQ:KPTI) rising 10.7 percent to $41.73 on news that its lead candidate, selinexor (KPT-330), demonstrated a disease control rate of 80 percent in 10 patients with relapsed and refractory aggressive non-Hodgkin's lymphoma (NHL).